Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Kornhuber, J. Articles by Riederer, P. Search for Related Content PubMed Citation Articles by Kornhuber, J. Articles by Riederer, P. Neurophysiology Other Neuroleptics

Persistence of Haloperidol in Human Brain Tissue

OBJECTIVE: After discontinuation of neuroleptic drugs, their antipsychotic and antiparkinsonian effects are still present for a prolonged period. It is not known whether the extended effects of neuroleptic drugs in humans are due to the continued presence of drug in brain tissue or to long-lasting drug-induced physiologic changes. The aim of this study was to directly examine haloperidol concentrations in human brain tissue in relation to drug-free time. METHOD: Haloperidol concentrations were measured in five regions (temporal cortex, cingulate gyrus, caudate nucleus, dentate nucleus, corpus callosum) of the postmortem brains of 11 patients previously treated with haloperidol. Haloperidol was analyzed by means of high-performance liquid chromatography with ultraviolet detection. The half-life in brain tissue was estimated by a population kinetic analysis. RESULTS: Haloperidol concentrations in the human brain tissue were 10–30 times higher than optimal serum concentrations used in the treatment of schizophrenia. Haloperidol concentrations appeared to be homogeneously distributed across different brain areas within a single patient. There was no apparent relation between duration of treatment and mean haloperidol concentration. Higher doses of haloperidol seemed to be related to higher concentrations in brain tissue. The elimination half-life from brain tissue was calculated to be 6.8 days. CONCLUSIONS: The results may have implications for clinical treatment decisions and the design of clinical research protocols. Patients exposed to haloperidol cannot be considered to be free of residual effects of the drug for a number of weeks after withdrawal.

This article has been cited by other articles:

				T. Meline and W. E. Harn Comments on Bothe, Davidow, Bramlett, Franic, and Ingham (2006) Am J Speech Lang Pathol, February 1, 2008; 17(1): 93 - 97. [Abstract] [Full Text] [PDF]

				P. HeiSer, F. Enning, J.-C. Krieg, and H. Vedder Effects of haloperidol, clozapine and olanzapine on the survival of human neuronal and immune cells in vitro J Psychopharmacol, November 1, 2007; 21(8): 851 - 856. [Abstract] [PDF]

				C. White, A. McPherson, M.-A. McCann, A. Sadler, and J. Fyvie Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic Palliative Medicine, April 1, 2006; 20(3): 215 - 216. [Abstract] [PDF]

				S.-B. Yang, F. Major, L. F. Tietze, and M. Rupnik Block of Delayed-Rectifier Potassium Channels by Reduced Haloperidol and Related Compounds in Mouse Cortical Neurons J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 352 - 362. [Abstract] [Full Text] [PDF]

				S. Kropp, V. Kern, K. Lange, D. Degner, G. Hajak, J. Kornhuber, E. Ruther, H. M. Emrich, U. Schneider, and S. Bleich Oxidative Stress During Treatment With First- and Second-Generation Antipsychotics J Neuropsychiatry Clin Neurosci, May 1, 2005; 17(2): 227 - 231. [Abstract] [Full Text] [PDF]

				M. C. Jockers-ScheruBl, U. Matthies, H. Danker-Hopfe, U. E. Lang, R. Mahlberg, and R. Hellweg Chronic Cannabis Abuse Raises Nerve Growth Factor Serum Concentrations in Drug-Naive Schizophrenic Patients J Psychopharmacol, December 1, 2003; 17(4): 439 - 445. [Abstract] [PDF]

				M. R. Gluck, R. G. Thomas, K. L. Davis, and V. Haroutunian Implications for Altered Glutamate and GABA Metabolism in the Dorsolateral Prefrontal Cortex of Aged Schizophrenic Patients Am J Psychiatry, July 1, 2002; 159(7): 1165 - 1173. [Abstract] [Full Text] [PDF]

				A. C. Lahti, H. H. Holcomb, D. R. Medoff, M. A. Weiler, C. A. Tamminga, and W. T. Carpenter Jr. Abnormal Patterns of Regional Cerebral Blood Flow in Schizophrenia With Primary Negative Symptoms During an Effortful Auditory Recognition Task Am J Psychiatry, November 1, 2001; 158(11): 1797 - 1808. [Abstract] [Full Text] [PDF]

				N. P. L. G. Verhoeff and S. Kapur The Role of Neuroimaging in Development of and Treatment With Antipsychotics Journal of Pharmacy Practice, August 1, 2001; 14(4): 332 - 340. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us